Results from a randomized controlled trial comparing a novel triple-combination topical therapy to standard hydroquinone treatment for melasma have shown significantly better outcomes with the combination approach.

Study Design

The 24-week study enrolled 450 patients with moderate-to-severe melasma, randomizing them to either the triple-combination therapy (containing a novel tyrosinase inhibitor, tranexamic acid, and a retinoid) or standard 4% hydroquinone cream.

Results

At 24 weeks, the triple-combination group showed a 65% improvement in MASI (Melasma Area and Severity Index) scores compared to 38% improvement in the hydroquinone group. Relapse rates were also lower in the combination group.

Clinical Significance

These results suggest a potential new first-line treatment option for melasma that may offer better sustained results without the long-term safety concerns associated with prolonged hydroquinone use.